ONDS stock rose +12% over the past 30 days, driven primarily by record Q1 2026 earnings with revenue surging over 1,000% year-over-year and raised full-year guidance. Quarterly performance shows +20% gain, supported by strategic acquisitions like Mistral and World View, boosting backlog to $457 million.

MUFG reported record-high net income of ¥2,427.2 billion for the fiscal year ended March 31, 2026 (FY2026), up 31.9% year-over-year (YoY). Net operating profits (NOP) surged 56.9% YoY to ¥2,377.2 billion, driven by customer segment growth and higher interest income.

Analysts expect Q1 2026 EPS of approximately $0.46, reflecting about 35% year-over-year growth. Consensus revenue forecast stands at around $850 million, up roughly 14% from Q1 2025.

Analysts expect Mizuho Financial Group (MFG) to report Q4 FY2025 earnings per share (EPS) around $0.07, with full-year consensus aligning closely to company guidance. Company guidance targets profit attributable to owners of parent at ¥1.13 trillion for FY2025 (April 1, 2025 – March 31, 2026), up 27.6% year-over-year.

Richtech Robotics has rebounded in recent weeks on EU expansion and high-profile demos at industry events. Partnerships with SoundHound AI and Vegas Golden Knights boost visibility in hospitality and sports venues.

Serve Robotics reported Q1 2026 revenue of $3.0 million, up 238% sequentially and 578% year-over-year, driven by fleet expansion and software services. The company completed its acquisition of Diligent Robotics, entering the healthcare robotics market and expanding to 44 cities across 14 states.

AUR shares have surged in recent weeks amid partnerships accelerating driverless truck deployments. Q1 2026 earnings beat EPS expectations with $1 million revenue; full-year guidance reaffirmed at $14-16 million.

Uber reported Q1 2026 gross bookings growth of 25% year-over-year, beating expectations despite regional headwinds. Stock rallied post-earnings on upbeat Q2 guidance for 18-22% bookings growth and strong profitability metrics.

MicroVision reported Q1 2026 revenue of $0.9 million, up 50% year-over-year, driven by increased sensor shipments across automotive, industrial, and defense sectors. Net loss narrowed to $25.3 million or $0.08 per share, with improved gross margins supporting full-year guidance of $10-15 million in revenue.

Eightco Holdings has pivoted to a tech-focused holding company with a $333 million treasury heavy in OpenAI equity, Worldcoin (WLD) tokens, and Ethereum (ETH). Recent treasury disclosures have driven volatile price action, with shares fluctuating between sub-$1 levels and intraday highs near $1.50 amid crypto and AI sentiment swings.

Strive Asset Management (ASST) has surged over 50% in recent weeks, driven by aggressive Bitcoin treasury expansions to 15,000 BTC. Analysts maintain a Strong Buy consensus with an average price target of $23.50, citing crypto exposure and capital structure improvements.

COIN shares experienced volatility in recent weeks, dipping after a Q1 earnings miss but rebounding on regulatory progress. Q1 revenue fell 31% year-over-year to $1.41 billion, missing estimates, with a net loss of $394 million or $1.49 per share (EPS).

Tempus AI reported Q1 2026 revenue growth of 36% year-over-year to $348.1 million, driven by diagnostics and data applications. Company raised full-year 2026 revenue guidance to $1.59–$1.60 billion, targeting ~$65 million in adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization).

Hims & Hers Health reported Q1 2026 revenue of $608.1 million, up 4% year-over-year but missing estimates, with a surprise net loss of $92.1 million due to higher costs from shifting to branded GLP-1 (glucagon-like peptide-1) weight-loss drugs. Shares dropped over 14% post-earnings amid margin pressure, though the company raised full-year 2026 revenue guidance to $2.8–$3.0 billion.

Recursion Pharmaceuticals reported Q1 2026 revenue of $6.47 million, missing estimates, with a net loss of $117.5 million but cash reserves of $665.2 million extending runway into early 2028. Clinical advancements include positive early data for REC-1245 (no dose-limiting toxicities) and REC-4881 (polyp reductions in familial adenomatous polyposis), alongside first dosing in REC-4539.

GFS stock surged +55% over the past 30 days, driven by strong Q1 earnings beat and AI-focused growth initiatives. Over the past quarter, shares gained +55%, reflecting recovery from early-year lows amid semiconductor demand recovery.

STM stock surged +56% over the past 30 days, driven by a strong Q1 earnings beat on revenue, upbeat Q2 guidance, and multiple analyst upgrades highlighting AI and automotive recovery. Over the past quarter, the stock rose +92%, fueled by semiconductor sector rally, AI data center demand, and strategic deals like the AWS partnership.

RKLB stock surged +80% over the past 30 days, driven by record Q1 revenue of $200.3 million (up 63.5% YoY) and a $2.2 billion backlog. Quarterly performance shows +74% gain, fueled by major defense contracts and analyst upgrades.

DDOG stock surged +70% over the past 30 days, driven primarily by blockbuster Q1 2026 earnings that beat estimates and raised full-year guidance. Over the past quarter, the stock rose +63%, reflecting recovery from earlier lows amid building AI demand for observability tools.

NOK stock surged +47% over the last 30 days, propelled by a Q1 earnings beat, robust AI and cloud revenue growth, and multiple analyst upgrades. Over the past quarter, shares advanced +109%, supported by expanding 5G deployments, optical network demand tied to AI infrastructure, and strategic partnerships.